Blog
Qizheng Tibetan Medicine Ranks Among the “Top 50 Valued Listed Companies on China’s SME Board”
Release time:
2019-08-13 16:00
On August 11, the 13th China Listed Companies Value Forum and the inaugural Investment Bank Forum Most Respected by Listed Companies, hosted by the Securities Times, were held in Shenzhen. Thanks to its outstanding financial performance, first-class corporate governance, a highly efficient management team, strategic planning that closely aligns with market demands, and strong brand value, Qizheng Tibetan Medicine successfully made it onto the “Top 50 Chinese SME Board Listed Companies by Value.”
Qizheng Tibetan Medicine is a leading domestic enterprise integrating research and development, production, and sales of Tibetan medicines. The company adheres to an academic-led, professionally driven approach and boasts 55 distinct Tibetan medicine formulations with 72 approved drug registration numbers, covering multiple specialty therapeutic areas in Tibetan medicine such as orthopedics, neurology, gynecology, and gastroenterology. It has a product portfolio centered around exclusive formulations or unique dosage forms. Since its launch, Qizheng Tibetan Medicine has remained firmly focused on its core business, achieving continuous and stable performance growth through organic internal development without relying on external leverage. The company closely aligns its strategic planning with evolving market demands, strengthening its analgesic plaster products and enriching its pain-management product line while exploring a dual-growth model that combines “organic expansion” with “external acquisitions.” As of the end of 2018, the company had achieved sales revenue of 1.213 billion yuan, net profit of 319 million yuan, total tax payments of 215 million yuan, and cumulative cash dividends totaling 1.437 billion yuan—nearly three times the amount raised in its initial public offering (IPO).
It is reported that the China Listed Companies Value Forum is a highly acclaimed value-discovery event with significant brand influence in China’s capital market. This year’s “China Listed Companies Value Selection” attracted participation from over 3,000 companies. Over the past 13 years, this selection has consistently identified and highlighted groups of listed companies that serve as valuable benchmarks in the capital market, firmly promoting the philosophy of value investing and lending its voice and support to the healthy development of a multi-tiered capital market.
Reporting media: Securities Times
Report link: http://www.p5w.net/news/cjzh/201908/t20190813_2328110.htm
Recommended News
2026-05-25
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO